Antifibrotic activity of bevacizumab on human tenon's fibroblasts in vitro

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 12, 2010, Pages 6524-6532

  O'Neill, Evelyn C ^a   Qin, Queena ^a   van Bergen, Nicole J ^a   Connell, Paul P ^a   Vasudevan, Sushil ^a,b   Coote, Michael A ^a   Trounce, Ian A ^a   Wong, Tina T L ^c   Crowston, Jonathan G ^a  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c Singapore National Eye Center and Singapore Eye Research Institute   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BEVACIZUMAB; BROXURIDINE; COLLAGEN; FLUOROURACIL; LACTATE DEHYDROGENASE;

ANTIFIBROSIS ACTIVITY; ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CELL VACUOLE; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG MECHANISM; FIBROBLAST; FIBROBLAST CONTRACTILITY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SCAR FORMATION; TENON CAPSULE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL COUNT; CELL PROLIFERATION; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; L-LACTATE DEHYDROGENASE; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; TENON CAPSULE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 79955957252     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5669     Document Type: Article

References (46)

1. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
2. Hitchings RA, Grierson I. Clinicopathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K. 1983; 103(pt 1):84-88.
3. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149-170.
4. Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol. 1989;108: 625-635.
5. Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol. 1991;109:1693-1698.
6. Skuta GL, Beeson CC, Higginbotham EJ, et al. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology. 1992;99:438-444.
7. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 1998;39:449-454.
8. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-346.
9. Senger DR, van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metast Rev. 1993; 12:303-324.
10. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 1994;180:341-346.
11. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
12. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37: 1929-1934.
13. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9:653-660.
14. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739.
15. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008;41:278-286.
16. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
18. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a metaanalysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122:1-7.
19. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502-508.
20. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
21. August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008;97:180-185.
22. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62:707-709.
23. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
24. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695, e1-e15.
25. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology. 2006;113:363-372, e5.
26. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9.
27. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular agerelated macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256.
28. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular agerelated macular degeneration: the second year of a prospective study. Am J Ophthalmol. 2009;148:59-65, e1.
29. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. 2009;19:607-612.
30. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2008;146:410-416.
31. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007;39:121-122.
32. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37:148-150.
33. Khaw PT, Ward S, Porter A, Grierson I, Hitchings RA, Rice NS. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2043-2052.
34. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152:1445-1452.
35. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1998;95:14389-14394.
36. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113: 1040-1050.
37. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312:549-560.
38. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-410.
39. Li Z, Van Bergen T, van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217-5225.
40. Lee KS, Park SJ, Kim SR, et al. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J. 2008;31:523-531.
41. Li ZD, Bork JP, Krueger B, et al. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol -kinase. Biochem Biophys Res Commun. 2005;334: 1049-1060.
42. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-590.
43. Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009;50:3233-3237.
44. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology. 2008;115:2141-2145, e2.
45. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-146.
46. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25:438-443.